{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:49:56Z","timestamp":1782928196722,"version":"3.54.5"},"reference-count":58,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients\u2019 growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.<\/ns4:p>","DOI":"10.12688\/f1000research.26083.1","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T10:55:21Z","timestamp":1598439321000},"page":"1049","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["The most recent advances in understanding and managing hidradenitis suppurativa"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0228-3262","authenticated-orcid":false,"given":"Shanthi","family":"Narla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0799-5680","authenticated-orcid":false,"given":"Alexis B.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3137-5601","authenticated-orcid":false,"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"76-90","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.","volume":"81","author":"A Alikhan","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"e342-e343","DOI":"10.1111\/jdv.16319","article-title":"Quality of life in people living with patients suffering from hidradenitis suppurativa.","volume":"34","author":"C Marasca","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1302-8","DOI":"10.1111\/jdv.16132","article-title":"Baseline patient-reported outcomes from UNITE: An observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice.","volume":"34","author":"A Kimball","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"e386-e388","DOI":"10.1111\/jdv.16290","article-title":"The impact of hidradenitis suppurativa on general health is higher than that of hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and depression.","volume":"34","author":"F Sampogna","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"427-36","DOI":"10.1007\/s00403-019-02025-5","article-title":"Factors affecting quality of life in patients with hidradenitis suppurativa.","volume":"312","author":"J J\u00f8rgensen AHR, Holm","year":"2020","journal-title":"Arch Dermatol Res."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"615-616","DOI":"10.1001\/jamadermatol.2020.0225","article-title":"Chronic Pain in Hidradenitis Suppurativa Explained Through the Process of Central Sensitization.","volume":"156","author":"K van Straalen","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref-7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis Suppurativa: An Update on Epidemiology, Phenotypes, Diagnosis, Pathogenesis, Comorbidities and Quality of Life.","author":"T Nguyen","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"S0190-9622(20)30989-0","DOI":"10.1016\/j.jaad.2020.05.114","article-title":"Proceeding report of the fourth Symposium on Hidradenitis Suppurativa Advances (SHSA) 2019.","author":"S Narla","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41702-019-0052-0","article-title":"Global prevalence of hidradenitis suppurativa and geographical variation\u2014systematic review and meta-analysis.","volume":"4","author":"K Phan","year":"2020","journal-title":"Biomed Dermatol."},{"key":"ref-10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19134","article-title":"Disease characteristics in female and male patients with hidradenitis suppurativa.","author":"A J\u00f8rgensen","year":"2020","journal-title":"Br J Dermatol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"S0190-9622(20)30562-4","DOI":"10.1016\/j.jaad.2020.04.022","article-title":"Patients with a familial predisposition to hidradenitis suppurativa have a distinct clinical phenotype.","author":"A Ravn J\u00f8rgensen","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"47-54","DOI":"10.12788\/j.sder.2017.017","article-title":"Pathophysiology of hidradenitis suppurativa.","volume":"36","author":"L Hoffman","year":"2017","journal-title":"Semin Cutan Med Surg."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jdv.16264","article-title":"Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific.","volume":"34","author":"C Zouboulis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1-5","DOI":"10.1001\/jamadermatol.2020.0777","article-title":"Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum.","volume":"156","author":"A Lyons","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"e5-e8","DOI":"10.1111\/jdv.15837","article-title":"Identifying anaemia in a cohort of patients with hidradenitis suppurativa.","volume":"34","author":"Y Soliman","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4162","article-title":"Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancy.","author":"A Adelekun","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1005-1006","DOI":"10.1001\/jamadermatol.2019.1105","article-title":"A Call to Accelerate Hidradenitis Suppurativa Research and Improve Care\u2014Moving Beyond Burden.","volume":"155","author":"H Naik","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"143-53","DOI":"10.1111\/ijd.14691","article-title":"Dietary and metabolic factors in the pathogenesis of hidradenitis suppurativa: A systematic review.","volume":"59","author":"F Choi","year":"2020","journal-title":"Int J Dermatol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00403-020-02053-6","article-title":"Clinical characteristics of pediatric hidradenitis suppurativa: A cross-sectional multicenter study of 140 patients.","volume":"21","author":"P Riis","year":"2020","journal-title":"Arch Dermatol Res."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1-9","DOI":"10.1001\/jamadermatol.2020.1047","article-title":"Association of Birth Weight, Childhood Body Mass Index, and Height With Risk of Hidradenitis Suppurativa.","volume":"156","author":"A J\u00f8rgensen","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"370-3","DOI":"10.1111\/pde.13466","article-title":"Hidradenitis suppurativa in children: The Henry Ford experience.","volume":"35","author":"T Braunberger","year":"2018","journal-title":"Pediatr Dermatol."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"886-91","DOI":"10.1111\/exd.13978","article-title":"Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa\/ acne inversa.","volume":"28","author":"J Frew","year":"2019","journal-title":"Exp Dermatol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"99-102","DOI":"10.1016\/j.jdcr.2019.10.010","article-title":"Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients.","volume":"6","author":"K Savage","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"289-295","DOI":"10.1159\/000503063","article-title":"Prevalence and Impact of Dietary Avoidance among Individuals with Hidradenitis Suppurativa.","volume":"236","author":"A Dempsey","year":"2020","journal-title":"Dermatology."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"296-297","DOI":"10.1159\/000504912","article-title":"Dietary Intervention: An Essential Part of the Management of Patients Affected by Hidradenitis Suppurativa.","volume":"236","author":"C Marasca","year":"2020","journal-title":"Dermatology."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/nu11010057","article-title":"Role of Nutrition and Adherence to the Mediterranean Diet in the Multidisciplinary Approach of Hidradenitis Suppurativa: Evaluation of Nutritional Status and Its Association with Severity of Disease.","volume":"11","author":"L Barrea","year":"2019","journal-title":"Nutrients."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"283-9","DOI":"10.1111\/ced.13732","article-title":"Post-bariatric surgery hidradenitis suppurativa: A new patient subset associated with malabsorption and micronutritional deficiencies.","volume":"44","author":"S Garcovich","year":"2019","journal-title":"Clin Exp Dermatol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"64-72","DOI":"10.1177\/1203475419874412","article-title":"Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review.","volume":"24","author":"A Sivanand","year":"2020","journal-title":"J Cutan Med Surg."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"366-76","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.","volume":"82","author":"A Garg","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"ref-30","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19131","article-title":"Hidradenitis suppurativa publications are sparse in frontline specialties.","author":"D Martins","year":"2020","journal-title":"Br J Dermatol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"421-6","DOI":"10.1007\/s00403-019-02027-3","article-title":"Hidradenitis suppurativa on Facebook: Thematic and content analyses of patient support group.","volume":"312","author":"S Fisher","year":"2020","journal-title":"Arch Dermatol Res."},{"key":"ref-32","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16536","article-title":"Emergency Doctor's ability to diagnose Hidradenitis suppurativa.","author":"D Bouazzi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1007\/s00403-020-02087-w","article-title":"Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis.","volume":"12","author":"P Singh","year":"2020","journal-title":"Arch Dermatol Res."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"744-7","DOI":"10.1111\/ijd.14870","article-title":"Comprehensive approach to managing hidradenitis suppurativa patients.","volume":"59","author":"E Collier","year":"2020","journal-title":"Int J Dermatol."},{"key":"ref-35","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16494","article-title":"Profile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes.","author":"F Deilhes","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"S0190-9622(20)30385-6","DOI":"10.1016\/j.jaad.2020.03.008","article-title":"Surgery is an essential aspect of managing patients with hidradenitis suppurativa.","author":"M Melendez Gonzalez","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jaad.2019.12.006","article-title":"Cryoinsufflation in the presurgical assessment of hidradenitis suppurativa.","volume":"82","author":"S Daveluy","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"422-34","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.","volume":"375","author":"A Kimball","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.jaad.2020.04.030","article-title":"Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.","volume":"83","author":"A Blaszczak","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"2040622319830646","DOI":"10.1177\/2040622319830646","article-title":"Topical, systemic and biologic therapies in hidradenitis suppurativa: Pathogenic insights by examining therapeutic mechanisms.","volume":"10","author":"J Frew","year":"2019","journal-title":"Ther Adv Chronic Dis."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"53-78","DOI":"10.2147\/BTT.S199862","article-title":"Systematic review of immunomodulatory therapies for hidradenitis suppurativa.","volume":"13","author":"S Lim","year":"2019","journal-title":"Biologics."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"345-348","DOI":"10.1001\/jamadermatol.2019.4595","article-title":"Complementary and Alternative Medicine Use in Patients With Hidradenitis Suppurativa.","volume":"156","author":"K Price","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"139-47","DOI":"10.1370\/afm.947","article-title":"'They Don't Ask Me So I Don't Tell Them': Patient-Clinician Communication About Traditional, Complementary, and Alternative Medicine.","volume":"7","author":"B Shelley","year":"2009","journal-title":"Ann Fam Med."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"1-16","DOI":"10.1159\/000503605","article-title":"A Comparison of International Management Guidelines for Hidradenitis Suppurativa.","author":"A Hendricks","year":"2019","journal-title":"Dermatology."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/bjd.17734","article-title":"Evidence-based hidradenitis suppurativa guidelines - and now all together please.","volume":"180","author":"G Jemec","year":"2019","journal-title":"Br J Dermatol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"483-91","DOI":"10.1111\/bjd.17716","article-title":"Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.","volume":"181","author":"L Thorlacius","year":"2019","journal-title":"Br J Dermatol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"2254-6","DOI":"10.1111\/jdv.15163","article-title":"Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.","volume":"32","author":"A Kimball","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"240-2","DOI":"10.1111\/bjd.18335","article-title":"Hidradenitis Suppurativa Area and Severity Index (HASI): A pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa.","volume":"182","author":"N Goldfarb","year":"2020","journal-title":"Br J Dermatol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"137-47","DOI":"10.23736\/S0392-0488.18.06021-2","article-title":"Patient-reported outcomes in hidradenitis suppurativa.","volume":"154","author":"G Vellaichamy","year":"2019","journal-title":"G Ital Dermatol Venereol."},{"key":"ref-50","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02074-1","article-title":"The utility of PROMIS domain measures in dermatologic care.","author":"F Esaa","year":"2020","journal-title":"Arch Dermatol Res."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1-6","DOI":"10.1159\/000504911","article-title":"Race and Ethnicity Gaps in Global Hidradenitis Suppurativa Clinical Trials.","author":"K Price","year":"2019","journal-title":"Dermatology."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1445-9","DOI":"10.1111\/j.1365-4632.2010.04638.x","article-title":"Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.","volume":"49","author":"M Arenbergerova","year":"2010","journal-title":"Int J Dermatol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"846-55","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: A parallel randomized trial.","volume":"157","author":"A Kimball","year":"2012","journal-title":"Ann Intern Med."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"391-8","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.","volume":"165","author":"I Miller","year":"2011","journal-title":"Br J Dermatol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"839-46","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: Clinical results and a search for potential biomarkers in serum.","volume":"174","author":"J Blok","year":"2016","journal-title":"Br J Dermatol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"538-40","DOI":"10.1111\/j.1600-0625.2009.00967.x","article-title":"Long-term efficacy of etanercept in hidradenitis suppurativa: Results from an open-label phase II prospective trial.","volume":"19","author":"A Pelekanou","year":"2010","journal-title":"Exp Dermatol."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"205-17","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial.","volume":"62","author":"A Grant","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"52-9","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.","volume":"152","author":"V Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-1049\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-1049\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-1049\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T13:00:08Z","timestamp":1598446808000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-1049\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":58,"URL":"https:\/\/doi.org\/10.12688\/f1000research.26083.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.28784.r69409","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.28784.r69408","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-1049\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.28784.r69409, Simon Francis Thomsen, Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, 26 Aug 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-1049\/v1#referee-response-69409","order":0,"name":"referee-response-69409","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.28784.r69408, Olivier Join-Lambert, Department of Microbiology, Caen Normandie University Hospital, Caen, France, 26 Aug 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-1049\/v1#referee-response-69408","order":1,"name":"referee-response-69408","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}